Stay updated on Pembrolizumab in Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Breast Cancer Clinical Trial page
- Check6 days agoChange DetectedAdded a Locations section including a Texas site (Houston, TX) and updated revision to v3.3.3; removed the HHS Vulnerability Disclosure link and the previous Texas Locations entry.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedUpdated revision label from v3.2.0 to v3.3.2 across the page, representing a minor platform version change without altering study content or its purpose. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedRemoved a notice about lapse in government funding and potential delays (operating status information) from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check56 days agoChange DetectedNew screenshot shows formatting and UI adjustments with updated timestamps but no changes to study details, eligibility criteria, or outcomes. There are no alterations to the primary endpoints or enrollment figures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check85 days agoChange Detected- Added a government operating-status notice and links, clarifying NIH Clinical Center operations and where to check updates. - Updated version from v3.1.0 to v3.2.0.SummaryDifference3%

- Check92 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Breast Cancer Clinical Trial page.